Wells Fargo
UTHR icon

Wells Fargo’s United Therapeutics UTHR Stock Holding History

Wells Fargo’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,000
Closed -$3.74M – 7415
2025
Q2 		$3.74M Buy
+13,000
New +$3.89M ﹤0.01% 2694

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Wells Fargo's UTHR Position: Q1 2026 in Review

Wells Fargo reduced its United Therapeutics (UTHR) stake by 15% in Q1 2026, selling an estimated $6.87M and leaving 77,138 shares worth $45.7M. The position accounts for 0.01% of the portfolio, ranked #1019.

Wells Fargo first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $110M in Q4 2017. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Wells Fargo held 77,138 shares of United Therapeutics worth $45.7M as of Q1 2026.
  • Wells Fargo sold 13,802 United Therapeutics shares in Q1 2026, an estimated $6.87M.
  • United Therapeutics made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1019 holding.
  • Wells Fargo first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's United Therapeutics position peaked at $110M in Q4 2017.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.